3rd IBDH Annual Midwest Symposium

3rd IBDH Annual Midwest Symposium is organized by IBDHorizons and will be held on Feb 29, 2020 at Hilton Columbus Downtown, Columbus, Ohio, United States of America.

Target Audience:
The target audience is comprised of healthcare providers caring for IBD patients: adult and pediatric gastroenterologists, advanced registered nurse practitioners and physician assistants, medical staff, dietician, surgeons, and pharmacists.

Accreditation:
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A maximum of 6.0 contact hours may be earned for successful completion of this activity.

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program has been assigned ACPE Universal Program # 0797-9999-20-002-L01-P. This program is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy education credit. Activity Type: Knowledge.

Statement of Need/Program Overview:
This activity is provided by IBDHorizons.
The management of IBD is highly dynamic with extensive, cutting-edge information deriving from a wealth of ongoing scientific, clinical, and therapeutic research programs. The mission of IBD Horizons® is to provide healthcare providers with the opportunity to enhance their clinical knowledge by providing the most up-to-date information regarding the management of IBD. Cutting edge topics delivered by respected educators/leaders in the IBD field, as well as opportunities for interaction between the presenters and participants, have been designed into the educational program.

Learning Objectives:
• Review the common extraintestinal manifestations in IBD apply practical approach to screen and intervene as needed
• Appraise the currently available evidence of the effect of Cannabis and supplements in IBD 
• Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy and special considerations when utilizing these therapies
• Describe and understand the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these options in IBD today
• Incorporate the concept of treat to target in IBD clinical practice and evaluate effectively how to incorporate into IBD management and goals of care
• Examine the current management of fibrostenotic Crohn’s complications and apply best up-to-date medical and surgical treatment strategies
• Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention
• Identify the most promising therapies including antibodies and small molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties 

It is a gathering of the topmost renowned doctors in the field of IBD. It is an opportunity not to be missed to meet and discuss key topics with a highly select group of 150-200 colleagues.

Topics and Speakers:
• Approach to Managing Common IBD Extraintestinal Manifestations - Dr. Millie Long
• Cannabis & Alternative Therapy in IBD: Good, Bad or ugly - Dr. Ghassan Wahbeh
• The Evolving World of non-biologic therapies - Dr. Scott D. Lee
• Comparative efficacy & positioning of IBD therapies today - Dr. Miguel Regueiro
• Application of the Treat-To-Target Concept in Clinical Practice - Dr. Anita Afzali
• Managing Fibrostenotic Crohn's Disease Complications - Dr. Christina Ha
• Approach to managing Dysplasia in IBD - Dr. Feza Remzi
• Promising Pathways and Upcoming Agents in IBD - Dr. Brian Feagan